MRVI - Maravai LifeSciences Holdings, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
MRVI price evolution
MRVI
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $574.96 | $579.61 | $580.18 | $628.27 |
| Short term investments | ||||
| Net receivables | $54.6 | $45.67 | $48.99 | $56.27 |
| Inventory | $51.4 | $49.14 | $47.4 | $54.82 |
| Total current assets | $699.91 | $700.87 | $699.31 | $765.51 |
| Long term investments | ||||
| Property, plant & equipment | $162.9 | $153.56 | $141.62 | $87.72 |
| Goodwill & intangible assets | $547.02 | $553.88 | $561.18 | $568.15 |
| Total noncurrent assets | $787.54 | $1566.69 | $1565.13 | $1549.88 |
| Total investments | ||||
| Total assets | $1487.45 | $2267.55 | $2264.44 | $2315.39 |
| Current liabilities | ||||
| Accounts payable | $10.73 | $9.42 | $6.66 | $4.78 |
| Deferred revenue | $3.36 | $2.55 | $2.46 | $2.05 |
| Short long term debt | $6.07 | $6.04 | $6 | $5.74 |
| Total current liabilities | $87.47 | $78.25 | $74.92 | $124.9 |
| Long term debt | $550.6 | $551.6 | $552.57 | $537.73 |
| Total noncurrent liabilities | $610.1 | $1297.02 | $1291.88 | $1289.85 |
| Total debt | $556.68 | $557.63 | $558.57 | $543.47 |
| Total liabilities | $697.57 | $1375.27 | $1366.8 | $1414.75 |
| Shareholders' equity | ||||
| Retained earnings | $285.74 | $391.7 | $398.16 | $404.7 |
| Other shareholder equity | ||||
| Total shareholder equity | $416.75 | $519.29 | $520.57 | $521.52 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $574.96 | $632.14 | $551.27 | $236.18 |
| Short term investments | ||||
| Net receivables | $54.6 | $146.81 | $117.51 | $51.02 |
| Inventory | $51.4 | $43.15 | $51.56 | $33.3 |
| Total current assets | $699.91 | $847.9 | $740.04 | $331.6 |
| Long term investments | ||||
| Property, plant & equipment | $162.9 | $116.59 | $46.33 | $101.31 |
| Goodwill & intangible assets | $547.02 | $500.33 | $270.34 | $401.93 |
| Total noncurrent assets | $787.54 | $1434.41 | $1178.24 | $939.09 |
| Total investments | ||||
| Total assets | $1487.45 | $2282.32 | $1918.28 | $1270.69 |
| Current liabilities | ||||
| Accounts payable | $10.73 | $5.99 | $8.15 | $8.17 |
| Deferred revenue | $3.36 | $3.09 | $10.21 | $78.06 |
| Short long term debt | $6.07 | $5.44 | $6 | $6 |
| Total current liabilities | $87.47 | $110.14 | $93.78 | $130.78 |
| Long term debt | $550.6 | $522 | $524.59 | $584.78 |
| Total noncurrent liabilities | $610.1 | $1266.93 | $1279.14 | $985.17 |
| Total debt | $556.68 | $527.44 | $530.59 | $590.78 |
| Total liabilities | $697.57 | $1737.1 | $1372.91 | $1115.94 |
| Shareholders' equity | ||||
| Retained earnings | $285.74 | $404.77 | $184.56 | $0.85 |
| Other shareholder equity | -$0.04 | |||
| Total shareholder equity | $416.75 | $545.22 | $315.5 | $88.51 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $74.14 | $66.86 | $68.91 | $79.03 |
| Cost of revenue | $35.11 | $36.69 | $43.27 | $33.68 |
| Gross Profit | $39.03 | $30.18 | $25.64 | $45.35 |
| Operating activities | ||||
| Research & development | $4.59 | $4.35 | $4.19 | $4.14 |
| Selling, general & administrative | $38.48 | $38.86 | $35.38 | $38.67 |
| Total operating expenses | $49.54 | $43.21 | $39.57 | $42.82 |
| Operating income | -$10.51 | -$13.03 | -$13.93 | $2.53 |
| Income from continuing operations | ||||
| EBIT | $675.61 | -$0.29 | -$0.94 | $8.59 |
| Income tax expense | $766.17 | -$5.46 | -$1.42 | -$3.17 |
| Interest expense | $15.4 | $11.64 | $7.02 | $11.83 |
| Net income | ||||
| Net income | -$105.96 | -$6.46 | -$6.54 | -$0.07 |
| Income (for common shares) | -$105.96 | -$6.46 | -$6.54 | -$0.07 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $288.94 | $883 | $799.24 | $284.1 |
| Cost of revenue | $148.74 | $168.96 | $140.56 | $79.65 |
| Gross Profit | $140.2 | $714.04 | $658.68 | $204.45 |
| Operating activities | ||||
| Research & development | $17.28 | $18.37 | $15.22 | $9.3 |
| Selling, general & administrative | $151.39 | $129.26 | $100.06 | $94.25 |
| Total operating expenses | $175.14 | $147.63 | $104.03 | $84.55 |
| Operating income | -$34.93 | $566.42 | $554.64 | $119.9 |
| Income from continuing operations | ||||
| EBIT | $682.97 | $301.43 | $273.81 | $122.59 |
| Income tax expense | $756.11 | $60.81 | $61.52 | $2.88 |
| Interest expense | $45.89 | $20.41 | $30.26 | $30.74 |
| Net income | ||||
| Net income | -$119.03 | $220.21 | $182.04 | $88.97 |
| Income (for common shares) | -$119.03 | $220.21 | $182.04 | $88.97 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$105.96 | -$6.46 | -$6.54 | -$0.07 |
| Operating activities | ||||
| Depreciation | $12.98 | $13.1 | $11.8 | $10.91 |
| Business acquisitions & disposals | $0.11 | -$69.73 | ||
| Stock-based compensation | $9.34 | $9.99 | $9.27 | $5.99 |
| Total cash flows from operations | $7.79 | $14.17 | $19.19 | $85.07 |
| Investing activities | ||||
| Capital expenditures | -$12.9 | -$15.52 | -$24.27 | $0 |
| Investments | ||||
| Total cash flows from investing | -$12.9 | -$15.52 | -$24.16 | -$69.73 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.33 | $0.31 | $0.02 | |
| Net borrowings | -$1.5 | -$1.48 | -$1.43 | -$1.36 |
| Total cash flows from financing | $0.47 | $0.78 | -$43.13 | -$19.21 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$4.64 | -$0.57 | -$48.1 | -$3.87 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$119.03 | $220.21 | $182.04 | $88.97 |
| Operating activities | ||||
| Depreciation | $48.78 | $38.1 | $33.54 | $25.84 |
| Business acquisitions & disposals | -$69.62 | -$238.35 | $119.96 | -$3.02 |
| Stock-based compensation | $34.59 | $18.67 | $10.46 | $24.63 |
| Total cash flows from operations | $126.22 | $535.98 | $368.57 | $152.19 |
| Investing activities | ||||
| Capital expenditures | -$52.69 | -$29.26 | -$14.3 | $9.09 |
| Investments | ||||
| Total cash flows from investing | -$122.31 | -$267.61 | $105.66 | $6.07 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.36 | $1.71 | $292.13 | |
| Net borrowings | -$5.77 | -$5.44 | -$6 | $187.63 |
| Total cash flows from financing | -$61.09 | -$187.5 | -$159.05 | $53.21 |
| Effect of exchange rate | -$0.09 | $0.02 | ||
| Change in cash and equivalents | -$57.18 | $80.87 | $315.09 | $211.48 |
News
Fundamentals
| Market cap | $1.83B |
|---|---|
| Enterprise value | $1.82B |
| Shares outstanding | 251.32M |
| Revenue | $288.94M |
|---|---|
| EBITDA | $731.75M |
| EBIT | $682.97M |
| Net Income | -$119.03M |
| Revenue Q/Q | -63.78% |
| Revenue Y/Y | -67.28% |
| P/E ratio | -15.41 |
|---|---|
| EV/Sales | 6.29 |
| EV/EBITDA | 2.48 |
| EV/EBIT | 2.66 |
| P/S ratio | 6.35 |
| P/B ratio | 4.40 |
| Book/Share | 1.66 |
| Cash/Share | 2.29 |
| EPS | -$0.47 |
|---|---|
| ROA | -5.71% |
| ROE | -24.07% |
| Debt/Equity | 1.67 |
|---|---|
| Net debt/EBITDA | 0.17 |
| Current ratio | 8.00 |
| Quick ratio | 7.41 |